Welcome to our dedicated page for Tscan Therapeutics news (Ticker: TCRX), a resource for investors and traders seeking the latest updates and insights on Tscan Therapeutics stock.
TScan Therapeutics, Inc. (TCRX) is a clinical-stage biopharmaceutical leader developing novel T cell receptor-engineered therapies for cancer treatment. This dedicated news hub provides investors and industry professionals with essential updates on the company's scientific advancements, regulatory progress, and strategic initiatives.
Access real-time information about TCRX's clinical trial developments, including updates on its liquid tumor and solid tumor therapy candidates. Stay informed about FDA designations, partnership announcements, and financial disclosures that shape the company's position in the competitive immunotherapy landscape.
Key coverage areas include breakthrough therapy designations, manufacturing innovations, preclinical data releases, and executive leadership updates. All content is curated to meet the needs of stakeholders requiring timely, accurate information about TCRX's progress in advancing TCR-T cell therapies.
Bookmark this page for centralized access to verified TScan Therapeutics announcements. Combine regular monitoring with SEC filings and earnings reports to maintain a complete perspective on the company's trajectory in precision oncology.
TScan Therapeutics announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead TCR-T therapy candidates, TSC-100 and TSC-101, for treating heme malignancies, including AML, ALL, and MDS. The RMAT designation is based on encouraging data from the ALLOHA trial and aims to expedite the development of transformative therapies. Both candidates target minor histocompatibility antigens HA-1 and HA-2 to eliminate malignant cells in patients undergoing allogeneic HCT with reduced intensity conditioning. Initial trial data show promising results with no relapse in treated patients and no dose-limiting toxicities observed.
TScan Therapeutics, Inc. (Nasdaq: TCRX) reported financial results for Q1 2024, dosing the first patient in its Phase 1 solid tumor program. All Phase 1 heme program patients remain relapse-free. A public offering raised $167.8 million, extending funds into Q4 2026. The company presented at major medical meetings and plans poster presentations at ASCO. TScan aims to advance heme and solid tumor programs with upcoming milestones.
TScan Therapeutics announced the dosing of the first patient in a Phase 1 clinical trial for TCR-T therapy targeting solid tumors, with initial data expected in 2024. The company aims to expand its ImmunoBank to enhance multiplex TCR-T therapy for solid tumors.
FAQ
What is the current stock price of Tscan Therapeutics (TCRX)?
What is the market cap of Tscan Therapeutics (TCRX)?
